(0.01%) 5 479.25 points
(-0.01%) 38 815 points
(0.05%) 19 931 points
(0.30%) $80.57
(0.54%) $2.80
(0.15%) $2 332.60
(-0.24%) $29.32
(-0.04%) $970.50
(0.00%) $0.932
(-0.14%) $10.64
(0.07%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases...
Stats | |
---|---|
Šios dienos apimtis | 83 889 |
Vidutinė apimtis | 52 473 |
Rinkos kapitalizacija | 25.48M |
EPS | $-0.130 ( Q3 | 2022-11-14 ) |
Last Dividend | $0.580 ( 2023-06-21 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.564 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0160 (2.75%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-23 | Klassen Preston | Sell | 842 211 | Common Stock |
2023-03-23 | Klassen Preston | Sell | 842 211 | Stock Option (right to buy) |
2023-01-26 | York Michael | Sell | 107 054 | Common Stock |
2023-01-26 | Klassen Preston | Sell | 380 605 | Common Stock |
2022-12-21 | Leonard Braden Michael | Buy | 120 099 | Common Stock |
INSIDER POWER |
---|
-22.47 |
Last 97 transactions |
Buy: 12 877 287 | Sell: 12 262 808 |
Tūris Koreliacija
Metacrine, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Metacrine, Inc. Koreliacija - Valiuta/Žaliavos
Metacrine, Inc. Finansinės ataskaitos
Annual | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.40 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.40 |
FY | 2020 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.436 |
FY | 2019 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.520 |
Financial Reports:
No articles found.
Metacrine, Inc. Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.580 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.580 | 2023-06-21 |
Last Dividend | $0.580 | 2023-06-21 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.580 | -- |
Avg. Dividend % Per Year | 43.27% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.580 | 129.80% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
21 Jun 2023 | $0.580 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.766 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.835 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 10.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 13.40 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 9.85 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.177 | -1.500 | 7.06 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -50.81 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.120 | 2.00 | -0.373 | -0.747 | [0 - 30] |
freeCashFlowPerShareTTM | -1.120 | 2.00 | -0.560 | -1.120 | [0 - 20] |
debtEquityRatioTTM | 0.246 | -1.500 | 9.01 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -3.34 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.578 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.400 | 1.000 | -0.141 | 0 | [1 - 100] |
returnOnEquityTTM | -0.835 | 2.50 | -6.68 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.120 | 2.00 | -0.373 | -1.120 | [0 - 30] |
dividendYielPercentageTTM | 99.76 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.120 | 2.00 | -0.373 | -0.747 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00400 | 1.500 | -3.36 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -0.917 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Metacrine, Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.